OR-002

OR-002 is a preclinical-stage drug candidate developed by OccamzRazor for the treatment of Parkinson's disease. Identified through the company's AI-driven "Razor" platform, which utilizes graph machine learning to map disease pathways, OR-002 is designed for a precision medicine approach targeting "Risk Allele Carriers." The program focuses on key genetic drivers of Parkinson's, including GBA, LRRK2, Alpha-synuclein (SNCA), and Parkin (PRKN). While the specific modality has not been publicly disclosed, the asset aims to modulate the underlying biological dysfunction associated with these genetic risk factors to slow or halt disease progression in specific patient subpopulations.